三阴性乳腺癌新辅助化疗后残留病灶肿瘤浸润淋巴细胞与残留癌负荷的预后意义
本研究合并四个未达病理完全缓解的三阴性乳腺癌新辅助化疗队列,评估残留病灶肿瘤浸润淋巴细胞对残留癌负荷预后价值的补充作用。共375例样本可评估,残留病灶肿瘤浸润淋巴细胞每增加10%与无复发生存和总生存改善显著相关,且在残留癌负荷II级中预后效应幅度大于III级。
要点
- 残留病灶肿瘤浸润淋巴细胞每增加10%,无复发生存HR为0.86(95%CI 0.79-0.92,P<0.001)。
- 残留病灶肿瘤浸润淋巴细胞每增加10%,总生存HR为0.87(95%CI 0.80-0.94,P<0.001)。
- 残留病灶肿瘤浸润淋巴细胞对含残留癌负荷分级的模型有显著附加预后价值,II级效应大于III级。
核心结论
- 三阴性乳腺癌残留病灶中的肿瘤浸润淋巴细胞水平与无复发生存和总生存改善显著相关,并为残留癌负荷分级提供附加预后信息,尤其在残留癌负荷II级中。
研究设计与样本
- 研究合并四个接受新辅助化疗后未达病理完全缓解的三阴性乳腺癌患者队列。
- 共375例残留病灶样本可评估肿瘤浸润淋巴细胞和残留癌负荷。
- 采用Cox模型分析残留病灶肿瘤浸润淋巴细胞(间质肿瘤浸润淋巴细胞作为连续变量,每10%增量)与无复发生存和总生存的关联,并用似然比检验评估附加预后价值。
主要发现
- 中位年龄50岁,62%接受蒽环类/紫杉类化疗。
- 新辅助化疗后残留癌负荷分级I、II、III级分别占11%、50%、39%。
- 残留病灶肿瘤浸润淋巴细胞中位水平为20%(IQR 10-40),与CD8+ T细胞密度呈正相关(ρ=0.41)。
- 肿瘤浸润淋巴细胞水平随新辅助化疗后肿瘤分期升高(P=0.005)和淋巴结分期升高(P=0.032)而显著降低,但按残留癌负荷分级无差异(P=0.84)。
- 残留病灶肿瘤浸润淋巴细胞每增加10%与无复发生存改善显著相关(HR 0.86;95%CI 0.79-0.92;P<0.001)和总生存改善显著相关(HR 0.87;95%CI 0.80-0.94;P<0.001),多因素分析中仍为显著预测因素(无复发生存P=0.032;总生存P=0.038)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased pathologic complete response (pCR) rates, and improved survival. We evaluated the added prognostic value of residual disease (RD) TILs to residual cancer burden (RCB) in predicting survival post-NAC. PATIENTS AND METHODS: We combined four TNBC NAC patient cohorts who did not achieve pCR. RD TILs were investigated for associations with recurrence-free survival (RFS), and overall survival (OS) using Cox models with stromal TILs as a continuous variable (per 10% increment). The likelihood ratio test was used to evaluate added prognostic value of RD TILs. RESULTS: A total of 375 RD TNBC samples were evaluable for TILs and RCB. The median age was 50 years, with 62% receiving anthracycline/taxane chemotherapy. The RCB class after NAC was 11%, 50%, and 39% for I, II, and III, respectively. The median RD TIL level was 20% (IQR 10-40). There was a positive correlation between RD TIL levels and CD8+ T-cell density (ρ = 0.41). TIL levels were significantly lower with increasing post-NAC tumor (P = 0.005), nodal stage (P = 0.032), but did not differ by RCB class (P = 0.84). Higher RD TILs were significantly associated with improved RFS (HR: 0.86; 95% CI 0.79-0.92; P < 0.001), and improved OS (HR: 0.87; 95% CI 0.80-0.94; P < 0.001), and remained significant predictors in multivariate analysis (RFS P = 0.032; OS P = 0.038 for OS). RD TILs added significant prognostic value to multivariate models including RCB class (P < 0.001 for RFS; P = 0.021 for OS). The positive prognostic effect of RD TILs significantly differed by RCB class for RFS (PInt=0.003) and OS (PInt=0.008) with a greater magnitude of positive effect observed for RCB class II than class III. CONCLUSIONS: TIL levels in TNBC RD are significantly associated with improved RFS and OS and add further prognostic information to RCB class, particularly in RCB class II.
引用
- Luen SJ, Salgado R, Dieci MV, et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol. 2019. PMID: 30590484. doi:10.1093/annonc/mdy547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。